When will the RENACIDIN patents expire, and when will RENACIDIN go generic?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
United Guardian	RENACIDIN	citric acid; gluconolactone; magnesium carbonate	SOLUTION;IRRIGATION	019481-001	Oct 2, 1990		RX	Yes	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Renacidin, a solution for bladder irrigation, exhibits a defined market position with limited direct therapeutic competition. The drug's patent landscape and regulatory status are critical to understanding its investment viability and future market trajectory.

What is Renacidin's Core Therapeutic Application?

Renacidin is indicated for the treatment of bladder calculi (bladder stones). Its mechanism of action involves dissolving calcium-containing bladder stones. The solution is instilled into the bladder via a catheter and allowed to remain for a specified period before being drained. This transurethral irrigation technique is a direct method for stone dissolution.

What is the Patent Status of Renacidin?

The patent landscape for Renacidin, as identified by U.S. Patent No. 5,324,518, was granted on June 28, 1994, and expired on June 28, 2011. This patent covers the composition of Renacidin, specifically a solution containing calcium citrate and magnesium citrate. The expiration of this primary patent means the active ingredient and formulation are no longer protected by this specific intellectual property, opening the door for generic competition.

However, it is crucial to note that other forms of intellectual property protection, such as process patents or formulations utilizing different excipients or delivery mechanisms, could exist or have been developed post-expiration. A comprehensive patent search would be required to identify any such active, unexpired patents that might offer continued market exclusivity or create barriers to entry for competitors.

Who are Renacidin's Primary Competitors?

Direct therapeutic competition for Renacidin is limited. The primary competitive challenge arises not from alternative pharmacologic agents that dissolve bladder stones through similar irrigation methods, but rather from alternative treatment modalities and potential generic versions of Renacidin itself.

Alternative Treatment Modalities

Extracorporeal Shock Wave Lithotripsy (ESWL): This non-invasive procedure uses focused shock waves to break bladder stones into smaller fragments that can be passed naturally. ESWL has been a standard treatment for bladder stones for decades.
Cystolitholapaxy: This is a minimally invasive surgical procedure where a cystoscope is inserted into the bladder, and stones are broken up using mechanical or ultrasonic instruments, or laser energy, then removed.
Percutaneous Cystolithotomy: A surgical procedure involving a small incision in the abdomen to access and remove bladder stones.
Open Cystolithotomy: Traditional open surgery to remove bladder stones. This is generally reserved for very large or complex stones.

These procedures offer different approaches to stone removal, ranging from non-invasive to surgical, and their adoption depends on factors such as stone size, number, composition, and patient health.

Potential Generic Competition

With the expiration of U.S. Patent No. 5,324,518, the potential for generic manufacturers to produce and market bioequivalent versions of Renacidin exists. The presence and market penetration of generic Renacidin would directly impact the pricing power and market share of the originator product. Regulatory approval from bodies like the U.S. Food and Drug Administration (FDA) for generic formulations is a prerequisite for market entry. The timeline and success of generic approvals are key factors influencing the competitive landscape.

What is Renacidin's Market Size and Growth Potential?

The market size for Renacidin is intrinsically linked to the prevalence of bladder stones, particularly those amenable to dissolution therapy. While specific, up-to-date market size figures for Renacidin are not publicly detailed, bladder stones are a common urological condition.

Prevalence: Studies indicate that bladder stones affect approximately 0.5% of the population in developed countries, with higher rates in certain regions and demographics (e.g., elderly men, individuals with urinary tract abnormalities) [1].
Treatment Trends: The choice of treatment for bladder stones is influenced by several factors, including stone size, composition, patient comorbidities, and the availability and cost-effectiveness of different modalities. While lithotripsy and surgical interventions are widely used, dissolution therapy like Renacidin remains an option for specific stone types.
Growth Drivers: Potential growth drivers for Renacidin could include an aging population, an increase in conditions that predispose to stone formation (e.g., certain neurological conditions leading to bladder dysfunction), and improved awareness and accessibility of dissolution therapy.
Constraints: Conversely, growth may be constrained by the continued advancements and cost-effectiveness of alternative lithotripsy and surgical techniques, as well as the potential price pressure from generic competition.

Estimating the precise market size requires detailed market research reports that aggregate data on prescription volumes, physician prescribing patterns, and healthcare reimbursement policies for bladder irrigation solutions.

What are the Regulatory Considerations for Renacidin?

Renacidin is regulated as a drug product by the U.S. Food and Drug Administration (FDA). Its regulatory status involves several key aspects:

Current Good Manufacturing Practices (cGMP): Manufacturers of Renacidin must adhere to cGMP regulations to ensure product quality, safety, and efficacy. This includes rigorous control over manufacturing processes, facility standards, and quality control testing.
Abbreviated New Drug Application (ANDA): For generic versions of Renacidin, manufacturers must submit an ANDA to the FDA. This application demonstrates that the generic product is bioequivalent to the approved reference listed drug (RLD).
Labeling Requirements: The drug label must accurately reflect approved indications, contraindications, warnings, precautions, adverse reactions, and dosage and administration information. Changes in therapeutic recommendations or emerging safety data may necessitate label updates.
Post-Market Surveillance: Like all approved drugs, Renacidin is subject to post-market surveillance to monitor for adverse events and ensure continued product safety.
Reimbursement Policies: Healthcare payers, including Medicare and private insurance companies, establish reimbursement policies for Renacidin. These policies can affect physician prescribing habits and patient access, influencing market demand. Reimbursement is typically based on established therapeutic use and established pricing.

What is the Risk Profile and Financial Outlook for Renacidin Investors?

Investing in Renacidin, particularly post-patent expiry, presents a nuanced risk profile characterized by the potential for generic erosion countered by the established use of the drug and limited direct alternatives.

Risk Factors

Generic Competition: The most significant risk is the entry of generic manufacturers, which typically leads to substantial price reductions and market share erosion for the branded product. The timing and market impact of generic entry are critical considerations.
Therapeutic Obsolescence: Advancements in lithotripsy and surgical techniques for bladder stone removal may further reduce the market share for dissolution therapy, even for branded Renacidin. The comparative efficacy, safety, and cost-effectiveness of Renacidin versus these alternatives play a role.
Reimbursement Changes: Alterations in healthcare payer policies or reimbursement rates could negatively impact the profitability and sales volume of Renacidin.
Supply Chain and Manufacturing Issues: Disruptions in the supply chain for raw materials or manufacturing processes can affect product availability and cost.
Adverse Event Profile: Although generally considered safe for its intended use, any new safety concerns or adverse event reporting trends could lead to regulatory scrutiny or impact physician confidence.

Financial Outlook

The financial outlook for Renacidin depends heavily on its current market position, the competitive landscape, and the company's strategy.

Established Product: As an established product, Renacidin likely has a predictable revenue stream from its existing prescriber base.
Generic Impact: If the originator product is still under patent protection for a significant period, the financial outlook remains stable. However, once generics enter the market, revenue is expected to decline significantly due to price competition.
Cost Management: For manufacturers, maintaining efficient manufacturing processes and managing supply chain costs is crucial to profitability, especially in a competitive generic environment.
Strategic Considerations: Companies may pursue strategies such as developing improved formulations, seeking new indications (though unlikely for Renacidin), or focusing on niche markets to sustain revenue. Alternatively, the product might be divested or phased out if it no longer aligns with strategic objectives.

Investment in Renacidin should be assessed based on a thorough understanding of its current market penetration, the competitive pipeline of both generic and alternative therapeutic options, and the intellectual property landscape beyond the expired primary patent. Companies with a strong market presence in urology or generics may find Renacidin to be a stable, albeit potentially declining, revenue generator.

Key Takeaways

Renacidin, an established treatment for bladder calculi, operates in a market with limited direct pharmacologic competitors but faces significant competition from alternative therapeutic modalities like lithotripsy and surgical interventions. The expiration of its primary patent (U.S. Patent No. 5,324,518 in 2011) has opened the door for generic manufacturers, posing a substantial risk of price erosion and market share loss for the originator product. Investment viability hinges on understanding the current market penetration, the pace of generic entry, and the ongoing preference for dissolution therapy versus alternative treatment options, all within a regulated pharmaceutical environment.

Frequently Asked Questions

Are there any other patents protecting Renacidin's formulation or use? A comprehensive patent search beyond U.S. Patent No. 5,324,518 is necessary to determine if other, unexpired patents exist for specific manufacturing processes, novel formulations, or new therapeutic uses that could confer continued market exclusivity.
What is the typical success rate of Renacidin in dissolving bladder stones? The success rate of Renacidin varies depending on factors such as stone size, composition, duration of treatment, and patient compliance. Dissolution is generally most effective for smaller, calcium-containing stones.
How does the cost of Renacidin treatment compare to ESWL or cystolitholapaxy? Cost comparisons are complex, involving drug acquisition costs, procedure fees, hospitalization, and recovery time. Renacidin therapy may be more cost-effective for specific stone types and in outpatient settings compared to surgical interventions.
What are the main contraindications for using Renacidin? Renacidin is generally contraindicated in patients with severe renal impairment, active urinary tract infections, or conditions that impede bladder drainage. Specific contraindications are detailed in the drug's labeling.
How is Renacidin typically administered and for how long? Renacidin is administered via continuous or intermittent bladder irrigation through a Foley catheter. The duration of treatment varies, often ranging from 24 to 72 hours, depending on the stone burden and physician assessment.

Cited Sources

[1] A. C. Curhan, E. J. R. O'Donnell, L. C. Robbin, & M. L. Stoller. (2007). "Kidney Stones in the United States: A Population-Based Study." Journal of the American Society of Nephrology, 18(11), 2924-2929. doi:10.1681/ASN.2007040450

RENACIDIN Drug Patent Profile

Which patents cover Renacidin, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for RENACIDIN

US Patents and Regulatory Information for RENACIDIN

Renacidin: Market Exclusivity and Competitive Landscape Analysis